Differential Diagnosis of Parkinson’s Disease and Atypical Parkinsonian Syndromes

Parkinson hastalığının klinik teşhisi, hastalığın ilk evrelerinde çoğunlukla Parkinson sendromu olarak yanlış tanı konan semptomların klasik sunumunu gösterir. Örtüşen iki hastalık arasındaki ayırıcı tanı için yenilikçi klinik araştırmalar, beyin görüntüleme, farmakolojik ilaçlar, derin beyin uyarımı ve beyin omurilik biyobelirteçlerini içermektedir. Günümüzde, hastalığın başlamasını geciktirirken semptomlarınında azaltılmasına yönelik tedavi seçenekleri mevcuttur. Bu makalede, Parkinson hastalığı ve atipik parkinson sendromları, semptomlar, etiyoloji, tanı ve tedavi ile ilişkili olarak kapsamlı bir şekilde tartışılmaktadır

Parkinson Hastalığı ve Atipik Parkinson Sendromlarının Ayırıcı Tanısı

Clinical diagnosis of Parkinson’s disease demonstrates classical presentation of symptoms that are often misdiagnosed as Parkinsonian syndromes predominately in the initial stages of the disease. Innovative clinical trials for the differential diagnosis between the two overlapping illnesses incorporate neuroimaging, pharmalogical medications, deep brain stimulation and cerebrospinal biomarkers. At present, therapeutic options are applicable in reducing symptomalogy while delaying the onset of the disease. In this article, Parkinson’s disease and atypical parkinsonian syndromes are comprehensively discussed in relations to symptoms, etiology, diagnosis and treatment

PDF

___

1. More SV, Choi D. Emerging preclinical pharmacological targets for Parkinson’s disease. Oncotarget.2016;7:29835–863.
2. Kriebel-gasparro A. Parkinson’s disease: update on medication management. J Nurse Pract. 2016;12:81-9.
3. Machado ARP, Zaidan HC, Paixao APS, Cavalheiro GL, Oliveria FHM, Barbosa Jr JAF et al. Feature visualization and classification for the discrimination between individuals with Parkinson’s disease under levodopa and DBS treatments. BioMed Eng Online.2016;15:169.
4. Krishna R, Ali M, Moustafa AA. Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease.Front Aging Neurosci. 2014;6:180.
5. Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clin Med (London). 2016;16:371- 5.
6. Cummings JL, Fine MJ, Grachev ID, Jarecke CJ, Johnson MK, Kuo PH et al. Effective and efficient diagnosis of parkinsonism: the roleof dopamine transporter SPECT imaging with Ioflupane I-123 injection (DaTscan). Am J Manage Care.2014;20 97-109.
7. Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016;86:13-24.
8. Hohler AD, Tsao JM, Katz DI, DiPiero TJ, Hehl CL, Leonard A et al. Effectiveness of an inpatient movement disorders program for patients with atypical parkinsonism. Parkinsons Dis. 2012:2012:871974.
9. Magdalinou N, Lees, AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry.2014;85:1065-75.
10. Broski SM, Hunt CH, Johnson GB, Morreale RF, Lowe VJ, Peller PJ. Structural and functional imaging in parkinsonian syndromes. Radiographics. 2014;34:1273–92.
11. Stamelou M, Hoeglinger GU. Atypical parkinsonism: an update. Curr Opin Neurol. 2013; 26:401– 5.
12. Moretti DV, Binetti G, Zanetti O, Frisoni GB. Rotigotine is safe and efficacious in atypical parkinsonism syndromes induced by both α-synucleinopathy and tauopathy. Neuropsychiatr Dis Treat.2014;10:1003–9.
13. Lieberman A, Deep A, Dhall R, Tran A, Liu MJ. Early freezing of gait: atypical versus typical parkinson disorders.Parkinsons Dis. 2015:2015:951645.
14. Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69:1445-52.
15. Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU. The differential diagnosis and treatment of atypical parkinsonism. Dtsch Ärztebl Int. 2016;113:61-9.
16. Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry.2015;86:1240-7.
17. Badoud S, Van De Ville D, Nicastro N, Garibotto V, Burkhard PR, Haller S. Discriminating among degenerative parkinsonisms using advanced 123I-ioflupane SPECT analyses. Neuroimage Clin. 2016;12:234–40.
18. Kim JM, Chung SJ, Kim JW, Jeon BS, Singh P, Thierfelder S et al. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study. BMC Neurol. 2015;15:17.
19. Herz DM, Haagensen BN, Nielsen SH, Madesen KH, Lokkegaard A, Siebener HR. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 2016;31:521-9.
20. Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E et al. Randomized trial of IPX066 carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Relat Disord. 2013;20:142-8.
21. Dashtipour K, Chen JJ, Kani C, Bahjri K, Ghamsary M. Clinical outcomes in patients with parkinson’s disease treated with a monoamine oxidase type B-inhibitor: a cross-sectional, cohort study.Pharmacotherapy, 2015;35:681-6.
22. Kurz C, Ebersbach G, Respondek G, Giese A, Arzberger T, Höglinger GU. An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. Acta Neuropathol Commun. 2016;4:120.
23. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis.Lancet Neurol. 2010;9:149-58.
24. Valadas JS, Vos M, Verstreken P. Therapeutic strategies in Parkinson’s disease: what we have learned from animal models. Ann N Y Acad Sci. 2014;1338:16-37.
25. Nolden LF, Tartavoulle T, Porche DJ. Parkinson's disease: assessment, diagnosis, and anagement. J Nurse Pract.2014;10:500-6.
26. Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH et al. The Addenbrooke’s Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry. 2013;84:544–51. ;
27. Yang Y, Tang B, Guo J. Parkinson’s disease and cognitive impairment. Parkinsons Dis. 2016;2016:6734678.
28. Seppi K, Weintraub D, Coelho M, Perez-Loret S, Fox S, Katzenschlager R et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord.2011:26:42-80.
29. Wood M, Dubois V, Scheller D, Gillard M. Rotigotine is a potent agonist at dopamine D1receptors as well as at dopamine D2and D3receptors. Br J Pharmacol. 2015;172:1124-35.
30. Schuepbach WMM, Rau J, Knudesen K, Volkmann J, Krack P, Timmermann L et al. Neurostimlation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368:610-22.
31. Mao Z, Hsu A, Gupta S, Mod, NB. Population pharmacodynamics of IPX066: an oral extendedrelease capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease. JClin Pharmacol. 2013;53:523-31.
32. Morales-Briceno H, Rodriguez-Violante M, Martinez-Ramirez D, Cervantes-Arriaga A. A reappraisal of the ten steps test for identifying atypical parkinsonism. Clin Neurol Neurosurg. 2014;119:1-3.
33. Gago MF, Fernandes V, Ferreira J, Silva H, Rodrigues ML, Rocha L et al. The effect of levodopa on postural stability evaluated by wearable inertial measurement units for idiopathic and vascular Parkinson'sdisease. Gait Posture. 2015;41:459-64.
34. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8:15-21.
35. Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79:55–65.
36. Oh M, Kim JS, Kim JY, Shin K, Park SH, Kim HO et al. Subregionalpatterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012;53:399-406.
37. Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M et al. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. J Nucl Med. 2015;56:234-42.
38. Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011;134:3146-66.
39. Morgan JC. Treatment strategies for Parkinson's disease. J Manage Care Med. 2013;16:81-4.
40. Vasta R, Nicoletti A, Mostile G, Dibilio V, Sciacca G, Contrafatto D et al. Side effects induced by the acute levodopa challenge in Parkinson’s disease and atypical parkinsonisms. Plos ONE. 2017;12:e0172145.
41. Katunina EA, Titova NV, Bezdolnyi YN, Shikkerimov RK, Gasanov MG, Burd SG et al. Dopamine receptor agonists: new formulation and new potential in the treatment of Parkinson’s disease. Neurosci Behav Physiol. 2016;46:971.
42. Hauser R, Silver D, Choudhry A, Eyal E, Isaacson S. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord. 2014;29:1028-34.
43. Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease. BMC Neurol.2016;16:90.
44. Aviles-Olmos I, Kefalopoulou Z, Tripoliti E, Candelario J, Akram H, Martinez-Torres I et al. Longterm outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry. 2014;85:1419-25.
45. Dewey RB, O’Suilleabhain PE, Sanghera M, Patel N, Khemani P, Lacritz LH et al. Developing a deep brain stimulation neuromodulation network for Parkinson disease, essential tremor, and dystonia: report of a quality improvement project. PLoS ONE.2016;11:e0164154.
46. Machado AG, Deogaonkar M, Cooper S. Deep brain stimulation for movement disorders: patient selection and technical options. Cleve Clin J Med.2012;79:19-24.
47. Servello D, Zekaj E, Saleh C, Menghetti C, Porta M. Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: report of three cases.Surg Neurol Int.2014;5:416-20.